Title:
CYCLIC CARBONATE NUCLEOSIDE COMPOUND AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/197791
Kind Code:
A1
Abstract:
The present invention relates to a cyclic carbonate nucleoside compound as represented by formula (I), and a pharmaceutically acceptable salt, a crystalline hydrate, a solvate or a tautomer thereof, and further disclosed are a pharmaceutical composition containing the compound and the use thereof. The compound and the pharmaceutical composition can be used for the treatment or prevention of virus infections, such as the treatment or prevention of virus infections related to coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus, novel coronavirus and/or feline coronavirus.
Inventors:
LI WEIZHANG (CN)
HAO LINGHUA (CN)
LI PENGHUI (CN)
ZHOU PEIYU (CN)
HAO LINGHUA (CN)
LI PENGHUI (CN)
ZHOU PEIYU (CN)
Application Number:
PCT/CN2023/080429
Publication Date:
October 19, 2023
Filing Date:
March 09, 2023
Export Citation:
Assignee:
GUANGDONG CHENKANG BIOTECHNOLOGY CO LTD (CN)
International Classes:
A61K31/706; C07H19/067; A61K31/7068; A61P31/12; A61P31/14; A61P31/16; A61P31/18; A61P31/22; C07H1/00; C07H9/02; C07H11/04; C07H13/04; C07H13/12
Domestic Patent References:
| WO2021167882A1 | 2021-08-26 |
Foreign References:
| CN115521337A | 2022-12-27 | |||
| CN115215914A | 2022-10-21 | |||
| US11541071B1 | 2023-01-03 | |||
| US20220081462A1 | 2022-03-17 | |||
| CN113929724A | 2022-01-14 | |||
| CN102015714A | 2011-04-13 | |||
| CN104884462A | 2015-09-02 |
Other References:
AESOP CHO, LIJUN ZHANG, JIE XU, RICK LEE, THOMAS BUTLER, SAMMY METOBO, VANGELIS AKTOUDIANAKIS, WILLARD LEW, HONG YE, MICHAEL CLARK: "Discovery of the First C -Nucleoside HCV Polymerase Inhibitor (GS-6620) with Demonstrated Antiviral Response in HCV Infected Patients", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 57, no. 5, 13 March 2014 (2014-03-13), US , pages 1812 - 1825, XP055257191, ISSN: 0022-2623, DOI: 10.1021/jm400201a
KUMAR GUDIPATI PAVAN, BISWAS SHYAMASRI, GOYAL PANKAJ: "ANTI HEPATITIS C VIRAL DRUGS REMDESIVIR AND UPRIFOSBUVIR DERIVATIVES ARE BETTER INHIBITORS OF SARS COV2 RNA-DEPENDENT RNA POLYMERASE DETERMINED BY DOCKING STUDIES", CHEMRXIV, 11 June 2020 (2020-06-11), XP093100021, DOI: \
KUMAR GUDIPATI PAVAN, BISWAS SHYAMASRI, GOYAL PANKAJ: "ANTI HEPATITIS C VIRAL DRUGS REMDESIVIR AND UPRIFOSBUVIR DERIVATIVES ARE BETTER INHIBITORS OF SARS COV2 RNA-DEPENDENT RNA POLYMERASE DETERMINED BY DOCKING STUDIES", CHEMRXIV, 11 June 2020 (2020-06-11), XP093100021, DOI: \
Attorney, Agent or Firm:
CN-KNOWHOW INTELLECTUAL PROPERTY AGENT LIMITED (CN)
Download PDF:
Previous Patent: MAP DISPLAY METHOD AND APPARATUS, AND ELECTRONIC DEVICE AND STORAGE MEDIUM
Next Patent: BATTERY
Next Patent: BATTERY